There will never be all mandatory payment models or all value-based models, but we can craft a value-based model around just about anything as long as everybody agrees on what the criteria is, said Lili Brillstein, CEO of Brillstein Collaborative Consulting, and former Director for Episodes of Care at Horizon Blue Cross Blue Shield of New Jersey.
There will never be all mandatory payment models or all value-based models, but we can craft a value-based model around just about anything as long as everybody agrees on what the criteria is, said Lili Brillstein, CEO of Brillstein Collaborative Consulting, and former Director for Episodes of Care at Horizon Blue Cross Blue Shield of New Jersey.
Transcript:
Do you think we will be seeing more mandatory payment models as opposed to voluntary models? Will we ever see exclusively mandatory payment models?
I think we will begin to see mandatory models. As I think about the evolution of the movement from fee-for-service to value-based care, from my perspective, it makes sense to start in a place where the providers have no risk and everybody has an opportunity to learn together how to create success in these models. They work best and everybody learns best, if the partners who are engaged in the models are those who have the propensity and the inclination and the willingness to change. Then, once the success is proven, to be able to share with other other partners who may come into the model, I think as that progression happens, and success is achieved, we'll begin to see more mandatorily required episodes in models. But I don't think that's going to happen immediately in any broad scale. As to the question around whether I think there will ever be all mandatory, I think absolutely not. I don't even think there will ever be all value-based care, I think there will remain some fee-for-service. I am a believer that we can craft a value-based model around just about anything, as long as you have a construct and everybody agrees on what the criteria is. But I think there will still always be some pieces of delivery that are going to be a fee-for-service.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More